Weekly Tactical Pick | Cadila Healthcare
Covid opportunity and a traction in complex pharma pipeline are big positives for Cadila16-04-2021
16-04-2021
Ramping production of Remdesivir to meet demand: Pharma firms
A Zydus Cadila spokesperson said, "The current spike in COVID-19 cases has led to a higher demand of Remdesivir. We are currently producing Remdesivir at three of our facilities. To cater to the demand we have ramped up our production from the earlier 5-6 lakh vials a month to 10-12 lakh vials a month, which we will scale towards 20 lakh vials a month.14-04-2021
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication with regard to the Notice to the shareholders for claiming their shares which are proposed to be transferred to Investor Education and Protection Fund ('IEPF')14-04-2021
CADILA HEALTHCARE LTD. - 532321 - Large Corporate Entity Disclosure
Large Corporate Entity Disclosure13-04-2021
Cadila Q4 PAT seen up 13.7% YoY to Rs. 505 cr: Sharekhan
Net Sales are expected to increase by 2.5 percent Y-o-Y (up 1.3 percent Q-o-Q) to Rs. 3,844 crore, according to Sharekhan.12-04-2021
India to have 5 more vaccines by Oct, Sputnik nod likely in 10 days: Report
New Delhi [India], April 11 (ANI): As more and more states flag shortage of COVID-19 vaccine doses, the Central government has pressed the accelerator to scale up vaccine production manifold.Top government sources told ANI that by end of the third quarter of this year, India will be getting vaccines from five additional manufacturers. India currently manufactures Covishield and Covaxin.Explaining the new strategy to manufacture additional vaccine doses, a source said "India currently has 2 COVID-19 vaccines being manufactured locally: Covishield and Covaxin, and we can expect five more vaccines by Q3 2021. These vaccines are Sputnik V vaccine (in collaboration with Dr. Reddy's), Johnson & Johnson vaccine (in collaboration with Biological E), Novavax vaccine (in collaboration with Serum India), Zydus Cadila's vaccine, and Bharat Biotech's Intranasal Vaccine. Safety and efficacy are the Union government's primary concerns while granting emergency use authorisation (EUA) to any...11-04-2021
CADILA HEALTHCARE LTD. - 532321 - Certificate Under Regulation 40(10)
Certificate under regulation 40(10) of the SEBI Listing Regulations, 2015.10-04-2021
Cadila Healthcare Ltd - 532321 - Shareholding for the Period Ended March 31, 2021
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here08-04-2021
Cadila Healthcare Ltd - 532321 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- Dhaval N SoniDesignation :- Company Secretary and Compliance Officer08-04-2021
CADILA HEALTHCARE LTD. - 532321 - Compliance Under Regulation 33 Of SEBI Listing Regulations, 2015
We would like to inform that the Company shall submit audited financial results for the entire financial year ended on March 31, 2021 within 60 days i.e. on or before May 30, 2021.08-04-2021